keyword
MENU ▼
Read by QxMD icon Read
search

rosuvastatin diabet

keyword
https://www.readbyqxmd.com/read/28611866/association-of-cognitive-impairment-in-patients-on-3-hydroxy-3-methyl-glutaryl-coa-reductase-inhibitors
#1
Satyajeet Roy, Joshua Louis Weinstock, Allyse Sachiko Ishino, Jefferson Felix Benites, Samantha Rachel Pop, Christopher David Perez, Edvard Adrian Gumbs, Jennifer Ann Rosenbaum, Mary Kate Roccato, Hely Shah, Gabriela Contino, Krystal Hunter
BACKGROUND: Atherosclerotic cardiovascular diseases are the leading cause of death in the United States. A reduction in cholesterol with 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors (statin) significantly reduces mortality and morbidity. Statins may be associated with cognitive impairment or dementia. Our aim was to study the association of cognitive impairment or dementia in patients who were on a statin. METHODS: Electronic medical records of 3,500 adult patients in our suburban internal medicine office were reviewed...
July 2017: Journal of Clinical Medicine Research
https://www.readbyqxmd.com/read/28588299/protective-effect-of-rosiglitazone-on-kidney-function-in-high-fat-challenged-human-crp-transgenic-mice-a-possible-role-for-adiponectin-and-mir-21
#2
Martine C Morrison, Gopala K Yakala, Wen Liang, Peter Y Wielinga, Kanita Salic, Arianne van Koppen, Tushar Tomar, Robert Kleemann, Peter Heeringa, Teake Kooistra
Obesity-related albuminuria is associated with decline of kidney function and is considered a first sign of diabetic nephropathy. Suggested factors linking obesity to kidney dysfunction include low-grade inflammation, insulin resistance and adipokine dysregulation. Here, we investigated the effects of two pharmacological compounds with established anti-inflammatory properties, rosiglitazone and rosuvastatin, on kidney dysfunction during high-fat diet (HFD)-induced obesity. For this, human CRP transgenic mice were fed standard chow, a lard-based HFD, HFD+rosuvastatin or HFD+rosiglitazone for 42 weeks to study effects on insulin resistance; plasma inflammatory markers and adipokines; and renal pathology...
June 6, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28574378/-impact-of-atorvastatin-and-rosuvastatin-on-residual-on-clopidogrel-treatment-platelet-reactivity-in-patients-with-ischemic-heart-disease-and-type-2-diabetes-mellitus-after-acute-coronary-syndrome
#3
T Ovrakh, S Serik, O Kochubiei
In patients with ischemic heart disease and type 2 diabetes mellitus in 4-6 weeks after acute coronary syndrome (ACS) on stable dual antiplatelet therapy (DAPT) with aspirin and clopidogrel co-adminstrated with rosuvastatin residual platelet reactivity on adenosine diphosphate was higher than in patients receiving atorvastatin. However, the rate of high residual on-clopidogrel treatment platelet reactivity (RCPR) in rosuvastatin-treated patients exceeded the rate of high RCPR in atorvastatin-treated patients insignificantly...
April 2017: Georgian Medical News
https://www.readbyqxmd.com/read/28515189/10-year-trends-in-statin-utilization-in-taiwan-a-retrospective-study-using-taiwan-s-national-health-insurance-research-database
#4
Hsing-Chun Hsieh, Jason C Hsu, Christine Y Lu
OBJECTIVE: Statins have been commonly used to treat patients with hypercholesterolaemia and to prevent cardiovascular disease (CVD) worldwide. This study examined trends in use of statins in Taiwan from 2002 to 2011. DESIGN: This is a retrospective observational study focusing on the utilisation of statins. SETTING: The monthly claims data for statins between 2002 and 2011 were retrieved from Taiwan's National Health Insurance Research Database...
May 17, 2017: BMJ Open
https://www.readbyqxmd.com/read/28511152/-pathogenetic-substantiation-of-complex-treatment-of-nonalcoholic-steatohepatitis-and-steatosis-in-patients-with-pre-diabetes-and-type-2-diabetes
#5
Іван В Чопей, Віталіна В Івачевська, Ксенія І Чубірко, Тарас І Гряділь, Михайло М Гечко
INTRODUCTION: Thesis is devoted to the optimization of complex treatment of nonalcoholic steatohepatitis and steatosis in patients with pre-diabetes and type 2 diabetes by acting on carbohydrate and lipid metabolism as well as providing hepatoprotection. AIM: Optimization of diagnostics and treatment in patients treatment of nonalcoholic steatohepatitis and steatosis in patients with pre-diabetes and type 2 diabetes. MATERIAL AND METHODS: Examination and treatment of 117 patients with NAFLD and pre-diabetes and type 2 diabetes was performed...
2017: Wiadomości Lekarskie: Organ Polskiego Towarzystwa Lekarskiego
https://www.readbyqxmd.com/read/28437620/american-association-of-clinical-endocrinologists-and-american-college-of-endocrinology-guidelines-for-management-of-dyslipidemia-and-prevention-of-cardiovascular-disease
#6
Paul S Jellinger, Yehuda Handelsman, Paul D Rosenblit, Zachary T Bloomgarden, Vivian A Fonseca, Alan J Garber, George Grunberger, Chris K Guerin, David S H Bell, Jeffrey I Mechanick, Rachel Pessah-Pollack, Kathleen Wyne, Donald Smith, Eliot A Brinton, Sergio Fazio, Michael Davidson
OBJECTIVE: The development of these guidelines is mandated by the American Association of Clinical Endocrinologists (AACE) Board of Directors and American College of Endocrinology (ACE) Board of Trustees and adheres with published AACE protocols for the standardized production of clinical practice guidelines (CPGs). METHODS: Recommendations are based on diligent reviews of the clinical evidence with transparent incorporation of subjective factors, according to established AACE/ACE guidelines for guidelines protocols...
April 2017: Endocrine Practice
https://www.readbyqxmd.com/read/28416099/statin-use-and-risk-of-new-onset-diabetes-a-meta-analysis-of-observational-studies
#7
M Casula, F Mozzanica, L Scotti, E Tragni, A Pirillo, G Corrao, A L Catapano
BACKGROUND AND AIMS: Meta-analyses of randomized control trials investigating the association between incident diabetes and statin use showed an increased risk of new-onset diabetes (NOD) from 9% to 13% associated with statins. However, short follow-up period, unpowered sample size, and lack of pre-specified diagnostic criteria for diabetes detection could be responsible of an underestimation of this risk. We conducted a meta-analysis of published observational studies to evaluate the association between statins use and risk of NOD...
May 2017: Nutrition, Metabolism, and Cardiovascular Diseases: NMCD
https://www.readbyqxmd.com/read/28406125/effect-of-rosuvastatin-on-dyslipidemia-and-other-parameters-associated-with-metabolic-syndrome-in-saudi-patients
#8
M M Rafeeq, H S Habib, Has Murad, M A Gari, Z J Gazzaz
CONTEXT: Metabolic syndrome (MS) is a constellation of metabolic irregularities consisting of dyslipidemia, hypertension, hyperglycemia, chronic inflammatory, and hypercoagulable state predisposing to diabetes and cardiovascular events. Statins are first-line drugs to treat the associated atherogenic dyslipidemia. AIM: Effect of rosuvastatin on MS in Saudi patients was studied. SETTINGS AND DESIGN: Prospective, open label, randomized clinical study...
April 2017: Nigerian Journal of Clinical Practice
https://www.readbyqxmd.com/read/28357773/centralized-pan-middle-east-survey-on-the-under-treatment-of-hypercholesterolemia-results-from-the-cepheus-ii-study-in-egypt
#9
Ashraf Reda, Alaa Etman, Ali Abdel-Rahim, Nabil Farag, Osama Sanad, Sameh Salamah
INTRODUCTION: As part of the CEPHEUS study, CEPHEUS I was conducted in 2010 and 2011 in Cairo and then the CEPHEUS II study was carried out in Alexandria and Delta Regions in Egypt between April 2014 and August 2015 to determine the proportion of dyslipidemic patients on lipid-lowering treatment reaching LDL-C treatment goals. METHODS: We conducted an open-label, observational, multicenter, cross-sectional survey where 90 investigators enrolled 1127 patients receiving lipid-lowering drugs for at least 3 months...
June 2017: Cardiology and Therapy
https://www.readbyqxmd.com/read/28277855/using-lower-cost-statins-improves-outcomes-for-normal-cholesterol-non-diabetic-patients
#10
Ronen Arbel, Dan Greenberg
BACKGROUND The American College of Cardiology recommends considering initiation of cholesterol-lowering therapy in normal cholesterol adults aged 45-70, who are either diabetic or have a 10 year atherosclerotic cardiovascular disease higher than 7.5%. Although this policy was shown to be cost-effective, the multi-billion dollar budget impact may limit the adoption, diffusion and overall clinical impact of this therapy. OBJECTIVES We examined whether using a substantially lower cost statin (Simvastatin) in a much wider population, while accepting almost-as-good per-patient outcomes can provide better outcomes for the entire intended use population (IUP) under a pre-specified budget constraint...
February 21, 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/28260863/pharmacokinetic-interactions-between-glimepiride-and-rosuvastatin-in-healthy-korean-subjects-does-the-slco1b1-or-cyp2c9-genetic-polymorphism-affect-these-drug-interactions
#11
RANDOMIZED CONTROLLED TRIAL
Choon Ok Kim, Eun Sil Oh, Hohyun Kim, Min Soo Park
To improve cardiovascular outcomes, dyslipidemia in patients with diabetes needs to be treated. Thus, these patients are likely to take glimepiride and rosuvastatin concomitantly. Therefore, this study aimed to evaluate the pharmacokinetic (PK) interactions between these two drugs in healthy males and to explore the effect of SLCO1B1 and CYP2C9 polymorphisms on their interactions in two randomized, open-label crossover studies. Glimepiride was studied in part 1 and rosuvastatin in part 2. Twenty-four participants were randomly assigned to each part...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28155189/diabetes-secondary-to-treatment-with-statins
#12
REVIEW
Markku Laakso, Johanna Kuusisto
PURPOSE OF REVIEW: This review summarizes the recent population-based studies, clinical trials, clinical metabolic studies, and genetic studies reporting the effects of statin therapy on the risk of diabetes. Recent studies aiming to explain the mechanisms how statin treatment affects insulin sensitivity and insulin secretion are also reviewed. RECENT FINDINGS: Statin therapy increases the risk of diabetes by 9%-12% in the two meta-analyses of statin trials and by 18%-99% in five population-based studies...
February 2017: Current Diabetes Reports
https://www.readbyqxmd.com/read/28029012/efficacy-of-moderate-intensity-statins-in-the-treatment-of-dyslipidemia-in-korean-patients-with-type-2-diabetes-mellitus
#13
Sung Hye Kong, Bo Kyung Koo, Min Kyong Moon
BACKGROUND: There has been evidences of ethnic differences in the low density lipoprotein cholesterol (LDL-C) lowering effect of statin. We aimed to evaluate the efficacy of moderate-intensity statins in the treatment of dyslipidemia among Korean patients with type 2 diabetes mellitus (T2DM). METHODS: We analyzed a retrospective cohort that consisted of Korean patients with T2DM aged 40 to 75 years who had been prescribed any of the moderate-intensity statins (atorvastatin 10 or 20 mg, rosuvastatin 5 or 10 mg, pitavastatin 2 mg, or pravastatin 40 mg)...
February 2017: Diabetes & Metabolism Journal
https://www.readbyqxmd.com/read/28025996/rosuvastatin-as-a-potential-preventive-drug-for-the-development-of-hepatocellular-carcinoma-associated-with-non-alcoholic-fatty-liver-disease-in-mice
#14
Keisuke Yokohama, Shinya Fukunishi, Masaaki Ii, Ken Nakamura, Hideko Ohama, Yusuke Tsuchimoto, Akira Asai, Yasuhiro Tsuda, Kazuhide Higuchi
Hepatocellular carcinoma (HCC) represents approximately 85% of all primary liver cancer cases. Non-alcoholic fatty liver disease (NAFLD) is one of the risk factors for HCC. NAFLD occurs in patients with components of metabolic syndrome, such as type 2 diabetes mellitus, obesity, hypertension and hyperlipidemia. Therefore, hyperlipidemia also represents a patient population at risk for HCC that can readily be identified. Rosuvastatin, a 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitor, has exhibited a more potent affinity for the active site of HMG-CoA reductase than other statins...
November 2016: International Journal of Molecular Medicine
https://www.readbyqxmd.com/read/27872642/rationale-and-design-of-rnafh-study-effect-of-rosuvastatin-10%C3%A2-mg-d-on-nonalcoholic-fatty-liver-in-metabolic-syndrome-patients-without-overt-diabetes-evaluated-by-1-h-magnetic-resonance-spectroscopy
#15
Fan Ping, Xuan Wang, Jing Yang, Mei-Cen Zhou, Wei Li, Ling-Ling Xu, Yu-Xiu Li
Objective. The RNAFH study (effect of rosuvastatin on nonalcoholic fatty liver disease in metabolic syndrome patients without overt diabetes evaluated by (1)H-MRS) is a prospective randomized, single-center, open-label trail designed to assess the effect of rosuvastatin on the intrahepatocellular lipid (IHCL) level of nonalcoholic fatty liver disease (NAFLD). Methods. 40 NAFLD patients meeting inclusion and exclusion criteria with metabolic syndrome (MS) but without overt diabetes mellitus will be included...
2016: International Journal of Endocrinology
https://www.readbyqxmd.com/read/27861386/statins-and-risk-for-new-onset-diabetes-mellitus-a-real-world-cohort-study-using-a-clinical-research-database
#16
Dukyong Yoon, Seung Soo Sheen, Sukhyang Lee, Yong Jun Choi, Rae Woong Park, Hong-Seok Lim
Although concern regarding the increased risk for new-onset diabetes mellitus (NODM) after statin treatment has been raised, there has been a lack of evidence in real-world clinical practice, particularly in East Asians. We investigated whether statin use is associated with risk for NODM in Koreans. We conducted a retrospective cohort study using the clinical research database from electronic health records. The study cohort consisted of 8265 statin-exposed and 33,060 matched nonexposed patients between January 1996 and August 2013...
November 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27830382/ticagrelor-and-rosuvastatin-have-additive-cardioprotective-effects-via-adenosine
#17
Yochai Birnbaum, Gilad D Birnbaum, Itamar Birnbaum, Sven Nylander, Yumei Ye
BACKGROUND: Ticagrelor inhibits the equilibrative-nucleoside-transporter-1 and thereby, adenosine cell re-uptake. Ticagrelor limits infarct size (IS) in non-diabetic rats and the effect is adenosine-dependent. Statins, via ecto-5'-nucleotidase activation, also increase adenosine levels and limit IS. HYPOTHESIS: Ticagrelor and rosuvastatin have additive effects on myocardial adenosine levels, and therefore, on IS and post-reperfusion activation of the NLRP3-inflammasome...
December 2016: Cardiovascular Drugs and Therapy
https://www.readbyqxmd.com/read/27798199/predictors-of-atherosclerotic-events-in-patients-on-haemodialysis-post-hoc-analyses-from-the-aurora-study
#18
Marit D Solbu, Geir Mjøen, Patrick B Mark, Hallvard Holdaas, Bengt Fellström, Roland E Schmieder, Faiez Zannad, William G Herrington, Alan G Jardine
BACKGROUND: Patients on haemodialysis (HD) are at high risk for cardiovascular events, but heart failure and sudden death are more common than atherosclerotic events. The A Study to Evaluate the Use of Rosuvastatinin in Subjects on Regular Hemodialysis: An Assessment of Survival and Cardiovascular Events (AURORA) trial was designed to assess the effect of rosuvastatin on myocardial infarction and death from any cardiac cause in 2773 HD patients. We studied predictors of the atherosclerotic cardiovascular events in AURORA...
October 17, 2016: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/27698930/statins-dose-dependently-exert-significant-chemopreventive-effects-against-various-cancers-in-chronic-obstructive-pulmonary-disease-patients-a-population-based-cohort-study
#19
Chun-Chao Chen, Yi-Ping Hsu, Ju-Chi Liu, Pai-Feng Kao, Li-Chin Sung, Chao-Feng Lin, Wen-Rui Hao, Shing-Hwa Liu, Szu-Yuan Wu
PURPOSE: Chronic obstructive pulmonary disease (COPD) is associated with an increased cancer risk. We evaluated the chemopreventive effect of statins against all cancers in COPD patients and identified the statin with the strongest chemopreventive effect. PATIENTS AND METHODS: All patients diagnosed with COPD at health care facilities in Taiwan (n = 116,017) from January 1, 2001, to December 31, 2012, were recruited. Each patient was followed to assess the following protective and risk factors for all cancers: age; sex; comorbidities (diabetes, hypertension, dyslipidemia) and the Charlson comorbidity index [CCI]); urbanization level; monthly income; and nonstatin drug use...
2016: Journal of Cancer
https://www.readbyqxmd.com/read/27652354/do-statins-really-cause-diabetes-a-meta-analysis-of-major-randomized-controlled-clinical-trials
#20
Alaa J Rahal, Ahmed I ElMallah, Rita J Poushuju, Rana Itani
OBJECTIVES: To investigate and establish the relationship between the use of statin therapy and the risk of development of diabetes.  METHODS: PubMed and the Cochrane Central Register of Controlled Trials was searched for randomized controlled end-point trials of statins, with more than 1000 subjects and a minimum of one-year follow-up period, published until August 2015. The odds ratio (OR) of diabetes incidence with overall statin therapy as well as with different statins in question was calculated through random effect meta-analysis model...
October 2016: Saudi Medical Journal
keyword
keyword
117897
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"